Moreover, Bafetinib is already known to inhibit the Bcr/Abl fusion protein tyrosine kinase and the Src-family member Lyn tyrosine kinase for treating Bcr-Abl+ leukemias, including chronic myelogenous leukemia (CML) and Philadelphia+ acute lymphoblastic leukemia [33,34]. Here, BCR is linked to leukemia.